14 stories mentioning CNC
Every FINWIRES story that references CNC, newest first.
Kenneth A Burdick, Director, on June 10, 2026, sold 80,000 shares in Centene (CNC) for $5,164,000. Following the Form 4 filing with the SEC, Burdick has control over a total of 283,584 common shares of the company, with 197,086 shares held directly and 86,498 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1071739/000107173926000127/xslF345X05/wk-form4_1781212935.xml
UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could benefit from improving utilization trends and potential artificial intelligence-driven efficiency gains across the healthcare system, Morgan Stanley said in a note Thursday.The firm said early signs of softer utilization have supported recent gains in managed-care stocks. The group has delivered a series of medical-loss-ratio beats in Q1 and some companies raising guidance. However, it noted that investors are still awaiting clearer confirmation of underlying trends and utilization signals remaining mixed ahead of Q2 results.AI adoption is increasingly embedded across managed-care operations, including prior authorization, call centers, provider portals, care management, pharmacy utilization and payment integrity.Morgan Stanley said UnitedHealth stands out as a leading "AI enabler," particularly through Optum Insight initiatives, which support both efficiency gains and potential revenue upside.The firm's scenario analysis assumes 0.5% to 2.0% AI-driven insurance margin expansion, which could translate into an illustrative 18% to 71% EPS upside across managed-care companies. It added that administrative workflows, particularly prior authorization, remain key areas of automation potential.Morgan Stanley boosted its price targets on UnitedHealth, CVS Health, Elevance Health (ELV), Centene (CNC), Molina Healthcare (MOH), and Humana (HUM).Price: $399.90, Change: $+22.90, Percent Change: +6.07%
Centene (CNC) and Molina Healthcare (MOH) have "compelling" EPS upside potential and could see their EPS jump four to six times higher by 2029, considering that Medicaid margins are likely bottoming in 2026, BofA Securities said in a Thursday note.BofA analysts said they expect Medicaid margins to improve as state data catches up to trends and changes in the risk pool, which should boost rates and margins in 2027 and onwards. Centene's 2026 EPS guidance of $3.40 is only about 30% of its current EPS power, while Molina's EPS guidance of $5 is only 17% of its current EPS power.If both companies can return to just the low end of their long-term Medicaid margin targets by 2029, their EPS should be up four to six times from 2026 guidance, the analysts said.Medicaid margin normalization is a historical pattern of slow but eventual catching up of rates, as states have an incentive to pay target margins to managed care organizations running Medicaid programs, but they take their time in doing so to avoid overpaying, the analysts said. Thus, they are confident that Medicaid margins will rebound in 2027.BofA kept the Centene's stock rating at buy and raised the price target to $72 from $60, as well as maintained Molina's stock rating at buy and price target at $250.Price: $57.99, Change: $-0.29, Percent Change: -0.50%
Centene (CNC) has an average rating of overweight and mean price target of $57.41, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $57.86, Change: $-0.41, Percent Change: -0.71%
Centene (CNC) has an average rating of overweight and mean price target of $56.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Centene (CNC) has an average rating of overweight and mean price target of $52.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $53.51, Change: $-0.18, Percent Change: -0.34%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $13 to $55, 16.2x our 2026 EPS estimate, above CNC's five- and 10-year historical forward averages of 12.8x and 13.9x, respectively. Our 2026 EPS estimate is up to $3.40 from $3.00, while our 2027 estimate is down $0.02 to $4.01. Shares jumped following a Q1 EPS beat and guidance raise, highlighted by a modest improvement in the health benefits ratio to 87.3% from 87.5% in the prior-year quarter. Results were aided by a more moderate flu/respiratory illness season, though persistent drivers of higher medical costs persist, such as behavioral health utilization and high-cost prescription drug volumes. As the nation's largest Medicaid insurer, CNC maintained a confident outlook despite looming challenges for membership and funding under the OBBBA legislation, in our view. Management called out the upcoming implementation of new Medicaid work requirements in Nebraska as a meaningful case study for potential impacts on other states.
Centene (CNC) has an average rating of overweight and mean price target of $51.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $52.76, Change: $+3.19, Percent Change: +6.44%
Centene (CNC) has an average rating of overweight and mean price target of $51.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $53.25, Change: $+3.68, Percent Change: +7.42%
Centene (CNC) has an average rating of overweight and mean price target of $51.06 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $52.19, Change: $+2.62, Percent Change: +5.28%
Centene (CNC) has an average rating of hold and mean price target of $49, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
US equity indexes closed lower on Tuesday as semiconductor shares fell and Middle East tensions lifted crude oil prices.* Arm Holdings (ARM), Applied Materials (AMAT), Lam Research (LRCX), Arista Networks (ANET), and Advanced Micro Devices (AMD) were among the tech decliners.* Iran's latest proposal to end the war in the Middle East failed to win President Donald Trump's support, Reuters reported, citing a US official.* The Conference Board's measure of consumer confidence rose to 92.8 in April from an upwardly revised 92.2 in March, compared with 89 expected in a Bloomberg survey.* The Richmond Fed's monthly manufacturing index rose to 3 in April from zero in March, above expectations for 1 in a Bloomberg poll.* May West Texas Intermediate crude oil rose $3.51 to settle at $99.88 per barrel, while June Brent crude, the global benchmark, was last seen up $2.90 at $111.13.* Alexandria Real Estate Equities (ARE) shares fell 11%, the biggest drop on the S&P 500, after the company reported lower Q1 results.* Centene (CNC) shares rose 13%, the top gainer on the S&P, after the company reported higher Q1 results and raised its 2026 outlook.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Centene reported Q1 adjusted EPS of $3.37 (+16.2% Y/Y), beating the consensus by $1.24, with the HBR improving 20 bps to 87.3% despite Marketplace membership declines from ACA enhanced premium tax credit expiration. Revenue rose 5.1% to $44.7B, due to premium yield improvements and Medicare PDP membership growth (+11.6% to 8.78M), while Commercial membership fell 33% to 4.06M. We view the 30 bps SG&A expense ratio improvement to 7.6% and $1.0B debt reduction as demonstrating effective expense management and disciplined capital allocation focused on debt reduction over share repurchases. Management raised 2026 adjusted EPS guidance to at least $3.40 from $3.00, supported by successful Medicaid performance, while maintaining HBR guidance midpoint at 91.3%. We look for more detail on looming Medicaid headwinds from the OBBBA legislation and management's outlook for the second half, as shares extended their rally off March lows with ~3% premarket gains.
Centene (CNC) has an average rating of hold and mean price target of $42.65, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $37.01, Change: $-0.25, Percent Change: -0.67%